Generic Name: fulvestrant

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: AstraZeneca

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Recommendation

Faslodex is an estrogen receptor downregulator approved for the treatment of hormone receptor-positive advanced or metastatic breast cancer in postmenopausal women.


General Info

The female hormone estrogen promotes the growth of hormone receptor-positive breast cancer. Faslodex works blocking these receptors and preventing estrogen from binding to cancer cells in the breast. It can also damage or reduce the number of estrogen receptors.

Faslodex is indicated for postmenopausal women with HR-positive, HER2-negative advanced breast cancer who were not previously treated with hormone therapy, those with HR-positive advanced cancer who progress after hormone therapy and those with HR-positive, HER2-negative progressive advanced or metastatic cancer in combination with CDK4/6 inhibitors. It was approved in 2002.


Dosage

Dosing Info: Faslodex is administered as an intramuscular injection in the buttocks. It is usually given on three days during the first month, then once monthly.


Side Effects

Common side effects include injection site pain, nausea, muscle, joint or bone pain, headaches and hot flashes. Potential serious side effects may include liver toxicity and bleeding in susceptible people. Faslodex should not be used during pregnancy.


For More Info: https://www.faslodex.com

Patient Assistance Program Info: https://www.faslodex.com/resources/metastatic-breast-cancer-support.html

Last Reviewed: December 6, 2018